Material composition alone can be used to direct human bone marrow stromal cells into distinct, zone-specific cell phenotypes and spatially-varying, multi-layered material scaffolds can generate complex, patterned tissue structures.
Studying cell behavior within 3D material niches is key to understanding cell biology in health and diseases, and developing biomaterials for regenerative medicine applications. Current approaches to studying these cell–material niches have low throughput and can only analyze a few replicates per experiment resulting in reduced measurement assurance and analytical power. Here, we report 3D material cytometry (3DMaC), a novel high-throughput method based on microfabricated, shape-specific 3D cell–material niches and imaging cytometry. 3DMaC achieves rapid and highly multiplexed analyses of very high replicate numbers (“n” of 104–106) of 3D biomaterial constructs. 3DMaC overcomes current limitations of low “n”, low-throughput, and “noisy” assays, to provide rapid and simultaneous analyses of potentially hundreds of parameters in 3D biomaterial cultures. The method is demonstrated here for a set of 85 000 events containing twelve distinct cell–biomaterial micro-niches along with robust, customized computational methods for high-throughput analytics with potentially unprecedented statistical power.
Total and viable microbial cell counts are increasingly important for applications including live biotherapeutic products, food safety, and probiotics. In microbiology, cells are quantified using methods such as colony forming unit (CFU), flow cytometry, and polymerase chain reaction (PCR), but different methods measure different aspects of the cells (measurands), and results may not be directly comparable across methods. In the absence of a ground-truth reference material for cell count, one cannot quantify the accuracy of any cell counting method, which limits method performance assessments and comparisons. Herein, a modified analysis of cell counting methods based on the ISO 20391-2:2019 standard was developed and demonstrated for microbial cell samples diluted over a log-scale range of concentrations. Escherichia coli samples ranging in concentration from ~5 x 105 cells/mL to 2 x 107 cells/mL were quantified using CFU, Coulter principle, fluorescence flow cytometry, and impedance flow cytometry. Quality metrics modified from the ISO standard were calculated for each method and shown to be repeatable across replicate experiments. The quality metrics illustrate large differences in proportionality and variability across methods, with total cell counts in good agreement and viable cell count having more variability. As the ISO standard is meant to guide fit-for-purpose method selection, interpretation of the results and quality metrics can drive method choice and optimization. The framework introduced here will help researchers select fit-for-purpose counting methods for quantification of microbial total and viable cells across a range of applications.
Total and viable microbial cell counts are increasingly important for applications including live biotherapeutic products, food safety, and probiotics. In microbiology, cells are quantified using methods such as colony forming unit (CFU), flow cytometry, and polymerase chain reaction (PCR), but different methods measure different aspects of the cells (measurands), and results may not be directly comparable across methods. In the absence of a ground-truth reference material for cell count, one cannot quantify the accuracy of any cell counting method, which limits method performance assessments and comparisons. Herein, a modified analysis of cell counting methods based on the ISO 20391-2:2019 standard was developed and demonstrated for microbial cell samples diluted over a log-scale range of concentrations. Escherichia coli samples ranging in concentration from approximately 5 × 10 5 cells/mL to 2 × 10 7 cells/mL were quantified using CFU, Coulter principle, fluorescence flow cytometry, and impedance flow cytometry. Quality metrics modified from the ISO standard were calculated for each method and shown to be repeatable across replicate experiments. The quality metrics illustrate large differences in proportionality and variability across methods, with total cell counts in good agreement and viable cell count having more variability. As the ISO standard is meant to guide fit-for-purpose method selection, interpretation of the results and quality metrics can drive method choice and optimization. The framework introduced here will help researchers select fit-for-purpose counting methods for quantification of microbial total and viable cells across a range of applications.
Although several genome editing options are available, CRISPR/Cas9 is one of the most commonly used systems for protein and advanced therapies. There are some long-term data regarding genomic and p... Method summary The objective of this work is to describe a protocol for using flow cytometry to measure the edits from CRISPR/Cas9 on a well-characterized B-lymphoblast cell line, GM24385, with the...
The NIST-led Rapid Microbial Testing Methods (RMTM) Consortium launched in 2020 to develop standards and measurement-based solutions to advance the use of RMTMs in advanced therapy products. In April 2024, NIST hosted the 4th annual workshop on RMTMs to update the community on RMTM Consortium efforts and to advance Consortium deliverables. This report provides a summary of workshop activities and findings. The workshop consisted of several working sessions, 1 h to 2 h in length, focused on specific Working Group activities and deliverables. Day 1 was open to the public, and Day 2 was for Consortium members only. Parties that participated in the workshop included advanced therapy producers, RMTM assay/instrument developers, and cell reference material producers. Progress was made on multiple Consortium activities via the session discussions, and feedback was provided to help scope potential future Consortium activities. Overall, the workshop helped ensure relevance and impact of RMTM Consortium activities.